The 24-h FEV1 time profile of olodaterol once daily via Respimat® and formoterol twice daily via Aerolizer® in patients with GOLD 2–4 COPD: results from two 6-week crossover studies
Crossref DOI link: https://doi.org/10.1186/2193-1801-3-419
Published Online: 2014-08-09
Published Print: 2014-12
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Feldman, Gregory J
Bernstein, Jonathan A
Hamilton, Alan
Nivens, Michael C
Korducki, Lawrence
LaForce, Craig
Text and Data Mining valid from 2014-08-09
Article History
Received: 11 February 2014
Accepted: 22 July 2014
First Online: 9 August 2014